A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.
- Read more about Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease ; study finds
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/patients-treated-with-monoclonal-antibodies-during-covid-19-delta-surge-had-low-rates-of-severe-disease
No comments:
Post a Comment